Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report

01 - Pre-Meeting Briefing prepared by NICE

02 - Submission from the technology manufacturer – Celgene

03 - NICE request to the manufacturer for clarification on their submission

04 - Manufacturer clarification response

05 - Consultee submission – Leukaemia CARE & MDS (joint submission)

06 - Consultee submission – Royal College of Physicians Submission

07 - Clinical expert personal perspective – Bowen

08 - Patient expert personal perspective – Pirilla

09 - Patient expert personal perspective – Taylor

10 - Evidence Review Group report prepared by Kleijnen systematic reviews

11 - Manufacturer factual accuracy check of Evidence Review Group report


Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

This page was last updated: 11 July 2013